Director – Health Economics and Outcomes Research
Corcept Therapeutics
Director – Health Economics and Outcomes Research
Corcept Therapeutics
develops cortisol-modulating therapies for Cushing's syndrome
For more than 25 years, Corcept has been singularly focused on the science of cortisol, a powerful hormone that when unregulated, can play a role in a broad range of diseases.
Our commercial portfolio includes treatments for hypercortisolism and oncology, and the company has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. With advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease, Corcept is unlocking the power of cortisol modulation to help address some of the most devastating diseases patients face today.
Corcept is headquartered in Redwood City, California. To learn more, visit www.corcept.com.
This position involves working cross-functionally with Medical Affairs, Market Access, and Clinical Development to ensure alignment between evidence generation and strategic objectives. This role offers the opportunity to drive scientific leadership and innovation, developing new methodologies and evidence strategies to enhance the understanding of the value of oncology treatments and advance the organization’s mission of delivering life-changing therapies to patients worldwide. This is a remote position.
Responsibilities:
Preferred Skills, Qualifications and Technical Proficiencies:
Preferred Education and Experience:
The pay range that the Company reasonably expects to pay for this remote position is $192,000 – $250,000; the pay ultimately offered may vary based on legitimate considerations, including geographic location, job-related knowledge, skills, experience, and education.
#LI-Remote
Applicants must be currently authorized to work in the United States on a full-time basis.
For information on how Corcept collects, uses, discloses, protects, and otherwise processes personal information and an explanation of the rights and choices available to you with respect to your personal information, please refer to our Privacy Notice link.
Corcept appreciates the commitment and hard work of all our team members as we strive to discover and develop novel treatments for patients with serious unmet medical needs.
Please visit our website at: https://www.corcept.com/
Corcept is an Equal Opportunity Employer
Corcept will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview. Though we use third-party tools to help with advertising our jobs, please be vigilant in checking that the communication is in fact coming from Corcept.
develops cortisol-modulating therapies for Cushing's syndrome
Corcept Therapeutics develops and commercializes cortisol modulators to treat disorders caused by abnormal cortisol levels. Its core product, Korlym (mifepristone), blocks cortisol’s action by acting as a cortisol receptor antagonist and is approved for hypercortisolism in Cushing’s syndrome. The company differentiates itself with a dedicated focus on cortisol modulation, an extensive pipeline of proprietary molecules, and ongoing development beyond Korlym. Its goal is to improve outcomes for patients with cortisol-related disorders by expanding access to effective therapies and advancing new treatments.
Explore more opportunities at Corcept Therapeutics